Adrenaline
发表于 2025-3-25 06:17:06
Designing non-clinical safety evaluation programmes: The view of the clinician,1. Experience with biotechnologically derived pharmaceuticals to treat auto-immune diseases provides an example of the pharmacological and safety information pertinent to first entry into man, and the relevance of animal data in support of early clinical trials.
AVOW
发表于 2025-3-25 07:35:04
http://reply.papertrans.cn/87/8605/860500/860500_22.png
giggle
发表于 2025-3-25 13:40:53
http://reply.papertrans.cn/87/8605/860500/860500_23.png
Anticonvulsants
发表于 2025-3-25 15:58:26
http://reply.papertrans.cn/87/8605/860500/860500_24.png
barium-study
发表于 2025-3-25 21:26:30
http://reply.papertrans.cn/87/8605/860500/860500_25.png
acquisition
发表于 2025-3-26 01:20:55
http://reply.papertrans.cn/87/8605/860500/860500_26.png
nauseate
发表于 2025-3-26 07:40:59
http://reply.papertrans.cn/87/8605/860500/860500_27.png
Venules
发表于 2025-3-26 11:50:38
978-94-010-6043-1Springer Science+Business Media Dordrecht 1998
轻而薄
发表于 2025-3-26 16:31:18
Centre for Medicines Research Workshophttp://image.papertrans.cn/s/image/860500.jpg
脱毛
发表于 2025-3-26 17:36:10
https://doi.org/10.1007/978-94-011-4876-4biotechnology; gene therapy; growth factor; interferon; research